Conditions Commonly Discussed in Medicinal Cannabis Consultations

Medicinal cannabis consultations in Australia may involve discussions around a range of chronic or complex health conditions where conventional management approaches have not provided adequate symptom control. Access to medicinal cannabis products requires assessment by a qualified healthcare practitioner and is regulated under Australian therapeutic frameworks.

Australian healthcare practitioners may consider medicinal cannabis as part of a broader treatment discussion depending on a patient’s medical history, current therapies, symptom profile, and individual clinical circumstances. Evidence supporting medicinal cannabis varies significantly between conditions, and not all patients will be considered suitable candidates. (Therapeutic Goods Administration (TGA))

Chronic Pain

Chronic non-cancer pain is among the most commonly discussed areas in medicinal cannabis consultations in Australia. This may include neuropathic pain, musculoskeletal pain, inflammatory conditions, or persistent pain syndromes that have proven difficult to manage using conventional therapies alone. (Therapeutic Goods Administration (TGA))

Healthcare practitioners may review:

• previous pain management approaches

• medication history

• functional impact on daily living

• sleep disruption

• quality of life considerations

Current Australian guidance notes that evidence for chronic pain remains variable and should be considered carefully within an individualised clinical context. (Therapeutic Goods Administration (TGA))

Epilepsy and Seizure Disorders

Certain severe and treatment-resistant epilepsy syndromes have been the subject of medicinal cannabis research internationally and within Australia. This area has some of the more established clinical evidence for cannabinoid-based therapies, particularly involving cannabidiol (CBD) formulations in carefully selected patients. (Epilepsy Action Australia)

Medicinal cannabis discussions in epilepsy care generally occur under specialist supervision and may involve:

• drug-resistant epilepsy

• seizure frequency management

• adjunctive treatment considerations

• ongoing neurological monitoring

Multiple Sclerosis

Some patients living with multiple sclerosis (MS) may discuss medicinal cannabis with healthcare practitioners in relation to symptoms such as:

• muscle spasticity

• chronic discomfort

• sleep disturbance

• mobility-related symptoms

Australian clinical guidance notes that evidence in MS symptom management remains mixed and patient suitability requires careful assessment. (RACGP)

Palliative and Supportive Care

Medicinal cannabis may also be discussed in palliative care settings where patients experience complex symptom burdens associated with advanced illness or supportive care needs. These discussions may involve:

• appetite changes

• nausea

• pain management

• overall comfort considerations

Healthcare practitioners assess these circumstances individually and within broader multidisciplinary care frameworks. (Therapeutic Goods Administration (TGA))

Chemotherapy-Related Nausea and Vomiting

Some medicinal cannabis research has explored its use in chemotherapy-induced nausea and vomiting where conventional anti-nausea treatments have not been fully effective. Discussions around these symptoms are generally conducted alongside oncology teams and existing treatment plans. (Therapeutic Goods Administration (TGA))

Sleep and Neurological Symptoms

Patients experiencing chronic sleep disruption or certain neurological symptoms may ask healthcare practitioners about medicinal cannabis during consultations. However, evidence supporting medicinal cannabis for insomnia, anxiety, and some mental health-related presentations remains limited and continues to evolve. (The Australian)

Australian practitioners are encouraged to carefully evaluate:

• underlying causes

• existing treatment pathways

• mental health history

• potential risks and interactions

Individual Assessment Remains Essential

Medicinal cannabis is not considered a first-line treatment for most conditions in Australia. Access pathways involve clinical assessment, consideration of existing therapies, and review of potential risks, side effects, and therapeutic appropriateness. Australian regulatory guidance emphasises that evidence quality differs substantially across conditions and that ongoing research continues to shape clinical understanding. (Therapeutic Goods Administration (TGA))

Patients seeking information about medicinal cannabis should discuss their circumstances with a qualified healthcare practitioner familiar with Australian prescribing pathways and current regulatory requirements.